½ÃÀ庸°í¼­
»óǰÄÚµå
1288778

¼¼°èÀÇ eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ ¹× ¿¹Ãø(2023-2030³â)

Global Electronic Clinical Outcome Assessment Solutions Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 128 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023-2030³âÀÇ Á¶»ç ±â°£ Áß 26.32%ÀÇ CAGR·Î 2022³â 41¾ï ´Þ·¯¿¡¼­ 2030³â¿¡´Â ¾à 335¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼ÇÀº ÀÓ»ó½ÃÇè ¹× ÀÇ·á ȯ°æ¿¡¼­ ȯÀÚ º¸°í °á°ú(PRO)¸¦ ¼öÁý, °ü¸® ¹× ºÐ¼®Çϱâ À§ÇÑ µðÁöÅÐ Åø ¹× ±â¼ú·Î, PRO´Â ȯÀÚ°¡ º¸°íÇÑ È¯ÀÚÀÇ °Ç°­ »óŸ¦ º¸°íÇÏ´Â °ÍÀ¸·Î, ÀÓ»óÀdzª ´Ù¸¥ »ç¶÷ÀÇ ÇØ¼®À» ¼ö¹ÝÇÏÁö ¾Ê½À´Ï´Ù. eCOA ¼Ö·ç¼ÇÀº ¼³¹®Áö, Àϱâ, ±âŸ ÀÚ°¡º¸°í µ¥ÀÌÅÍ¿Í °°Àº ÀüÅëÀûÀÎ Á¾ÀÌ ±â¹Ý PRO ¼öÁý ¹æ¹ýÀ» ´ëüÇϱâ À§ÇØ ¼³°èµÇ¾úÀ¸¸ç, À¥ ±â¹Ý, ¸ð¹ÙÀÏ ¿ëµµ, ÀüÀÚ ´ÙÀ̾, ¿þ¾î·¯ºí ±â±â µîÀ» ÅëÇØ PRO¸¦ ¼öÁýÇÏ°í °ü¸®ÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù. eCOA ¼Ö·ç¼ÇÀº À¥ ±â¹Ý, ¸ð¹ÙÀÏ ¿ëµµ, ÀüÀÚ ´ÙÀ̾, ¿þ¾î·¯ºí ±â±â µî ´Ù¾çÇÑ ÇüÅ·ΠÁ¦°øµÇ¸ç, ÀÓ»ó½ÃÇè, ȯÀÚ µî·Ï, ÀÏ»ó Áø·á µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼­ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÀÇ·á ¼­ºñ½º ÇÁ·Î¹ÙÀÌ´õ´Â ȯÀÚ º¸°í °á°ú(PRO)¿Í ȯÀÚ ¸¸Á·µµ¿¡ ´õ ÁßÁ¡À» µÐ ȯÀÚ Áß½É Ä¡·á¸¦ Á¦°øÇÏ´Â µ¥ Á¡Á¡ ´õ ÁýÁßÇϰí ÀÖÀ¸¸ç, eCOA ¼Ö·ç¼ÇÀº ȯÀÚ °æÇè¿¡ ´ëÇÑ ±ÍÁßÇÑ ÀλçÀÌÆ®À» Á¦°øÇÒ ¼ö ÀÖ´Â PROÀÇ ¼öÁýÀ» ÃËÁøÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÇコÄÉ¾î ¾÷°è´Â ÀÓ»ó½ÃÇè ¹× ±âŸ ¿¬±¸ Ȱµ¿¿¡¼­ ÀüÀÚ µ¥ÀÌÅÍ ¼öÁý(EDC) ¼Ö·ç¼ÇÀ» µµÀÔÇϰí ÀÖÀ¸¸ç, eCOA ¼Ö·ç¼ÇÀº EDCÀÇ ÀÚ¿¬½º·¯¿î ¿¬Àå¼±»ó¿¡¼­ ȯÀÚ º¸°í °á°ú ¹× ±âŸ µ¥ÀÌÅ͸¦ µðÁöÅÐ Çü½ÄÀ¸·Î ¼öÁýÇÒ ¼ö ÀÖ°Ô ÇØÁÝ´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹(FDA), À¯·´ÀǾàǰû(EMA) µî ±ÔÁ¦ ±â°ü¿¡¼­ ÀÓ»ó½ÃÇè¿¡ eCOA ¼Ö·ç¼Ç »ç¿ëÀ» ´Ã¸®¸é¼­ ±ÔÁ¦ °¡À̵å¶óÀÎÀ» ÁؼöÇÏ´Â eCOA ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. eCOA ¼Ö·ç¼ÇÀº ÀÓ»ó½ÃÇè ¹× ±âŸ ¿¬±¸ Ȱµ¿°ú °ü·ÃµÈ ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖÀ¸¸ç, ¿þ¾î·¯ºí ±â±â ¹× ±âŸ ¼¾¼­ ±â¼úÀÇ È°¿ë µî ´Ù¾çÇÑ ±â¼ú ¹ßÀüÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. eCOA ¼Ö·ç¼ÇÀº µ¥ÀÌÅÍ ¼öÁýÀ» °£¼ÒÈ­Çϰí Á¾ÀÌ ±â¹Ý ÇÁ·Î¼¼½ºÀÇ Çʿ伺À» ÁÙÀÓÀ¸·Î½á È¿À²¼ºÀ» ³ôÀÌ°í ºñ¿ëÀ» Àý°¨ÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â Portre's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®¿¡ ´ëÇØ ¼³¸íÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ÅøÀº ¾÷°è ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·Âµµ¸¦ Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ ÅøÀº ¼¼°èÀÇ eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå¿¡¼­ °¢ ºÎ¹®À» Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ ¿¬±¸¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

Áö¿ªº° ºÐ¼® :

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀüÀÚ Ä¡·á ¼º°ú Æò°¡ ¼Ö·ç¼Ç ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¿¡ ÃÊÁ¡À» ¸ÂÃá Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¿ëµµ ºÎ¹® ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ÀÌ Á¶»ç º¸°í¼­´Â ½ÃÀå ÁÖ¿ä ±â¾÷ÀÇ Á¾ÇÕÀû °³¿ä¿Í ¼¼°è °æÀï ȯ°æ¿¡ ´ëÇÑ ÀÚ¼¼ÇÑ °üÁ¡À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ ¼½¼ÇÀº ÁÖ¿ä M&A, ¹Ì·¡ ¿ª·®, ÆÄÆ®³Ê½Ê, À繫 °³¿ä, Çù¾÷, ½ÅÁ¦Ç° °³¹ß, ½ÅÁ¦Ç° Ãâ½Ã µî ´Ù¾çÇÑ Àü·«Àû ¹ßÀüÀ» Æ÷ÇÔÇÑ °æÀï ±¸µµÀÇ ÀüüÀûÀÎ °üÁ¡À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

  • º» º¸°í¼­ÀÇ ³»¿ë
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • ½ÃÀå Á¶»ç ÇÁ·Î¼¼½º
    • ½ÃÀå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀåÀÇ ½º³À¼ô

Á¦3Àå eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç - »ê¾÷ ºÐ¼®

  • ¼­·Ð - ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • »ê¾÷ µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀåÀÇ ¸Å·Â ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·áÀÇ °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • ´ÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ÀδÙÀÌ·ºÆ® ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³ÎÀÇ µ¿Çâ

Á¦5Àå COVID-19ÀÇ ¹ß»ýÀÇ ¿µÇ⠺м®

Á¦6Àå ¼¼°èÀÇ eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : µô¸®¹ö¸® ¸ðµåº°

  • µô¸®¹ö¸® ¸ðµåº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • µô¸®¹ö¸® ¸ðµåº° ºÐ¼®
  • ¿ÂÇÁ·¹¹Ì½º
  • À¥ & Ŭ¶ó¿ìµå ±â¹Ý

Á¦7Àå ¼¼°èÀÇ eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • ÃÖÁ¾»ç¿ëÀÚº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾»ç¿ëÀÚº° ºÐ¼®
  • º´¿ø/ÇコÄɾî ÇÁ·Î¹ÙÀÌ´õ
  • CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü)
  • Á¦¾àȸ»ç¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ÀÇ·á±â±â Á¦Á¶¾÷ü
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹ÌÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ÆÇ¸Å ºÐ¼®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • UAE
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ

Á¦9Àå eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ±â¾÷ÀÇ °æÀï ±¸µµ

  • eCOA(Electronic Clinical Outcome Assessment) ¼Ö·ç¼Ç ½ÃÀå °æÀï
  • Á¦ÈÞ¡¤Çù·Â¡¤ÇÕÀÇ
  • ÇÕº´¡¤Àμö
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • »óÀ§ ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • IBM
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° ¼Ò°³
    • ÃÖ±Ù °³¹ß »óȲ
  • IQVIA Inc.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Medidata Solutions Inc.
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Clario
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • ArisGlobal
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Signant Health
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • TransPerfect
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Cloudbyz
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • Clime do Health GmbH
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù °³¹ß »óȲ
  • ClinCapture
    • ȸ»ç °³¿ä
    • ±â¾÷ ¸ÅÃâ
    • Á¦Ç° Á¤º¸
    • ÃÖ±Ù µ¿Çâ

ÁÖ : ±â¾÷ °³¿ä¿¡¼­ À繫ÀÇ »ó¼¼ ³»¿ª°ú Ãֽа³¹ßÀº ÀÔ¼ö »óȲ¿¡ µû¶ó Á¦°ø °¡´ÉÇϳª ºñ°ø°³ ȸ»çÀÇ °æ¿ì, ´Ù·çÁö ¾ÊÀ» ¼ö ÀÖ½À´Ï´Ù.

KSA 23.07.05

The global demand for Electronic Clinical Outcome Assessment Solutions Market is presumed to reach the market size of nearly USD 33.58 BN by 2030 from USD 4.1 BN in 2022 with a CAGR of 26.32% under the study period 2023-2030.

Electronic Clinical Outcome Assessment (eCOA) solutions are digital tools and technologies used to collect, manage, and analyze patient-reported outcomes (PROs) in clinical trials and healthcare settings. PROs reports the status of a patient's health condition as reported by the patient. It does to accompany an interpretation by a clinician or anyone else. These may include patient-reported symptoms, quality of life measures, treatment satisfaction, and more. eCOA solutions are designed to replace traditional paper-based methods of collecting PROs, such as questionnaires, diaries, and other forms of self-reported data. They offer a number of advantages over paper-based methods, including increased accuracy, data completeness, and data quality, as well as more efficient data collection, improved patient engagement, and faster data analysis. eCOA solutions can take a variety of forms, including web-based and mobile applications, electronic diaries, and wearable devices. They may include features such as real-time alerts, interactive questionnaires, and multimedia content. eCOA solutions may also include software for data management, analysis, and reporting. eCOA solutions are used in a variety of settings, including clinical trials, patient registries, and routine clinical care.

Market Dynamics:

Healthcare providers are increasingly focused on providing patient-centric care, which involves a greater emphasis on patient-reported outcomes (PROs) and patient satisfaction. eCOA solutions can help facilitate the collection of PROs, which can provide valuable insights into the patient experience. The healthcare industry is increasingly adopting electronic data capture (EDC) solutions for clinical trials and other research activities. eCOA solutions are a natural extension of EDC, allowing for the capture of patient-reported outcomes and other data in a digital format. Regulatory agencies (U.S. Food and Drug Administration & the European Medicines Agency) are increasingly using the of eCOA solutions in clinical trials promoting demand for eCOA solutions that are compliant with regulatory guidelines. The eCOA solutions market is being driven by a range of technological advancements, including the development of mobile and web-based platforms, as well as the use of wearable devices and other sensor technologies. These advancements are making it easier and more convenient to collect patient-reported outcomes in a digital format. eCOA solutions can help reduce the costs associated with clinical trials and other research activities. By streamlining data collection and reducing the need for paper-based processes, eCOA solutions can help improve efficiency and reduce costs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of electronic clinical outcome assessment solutions. The growth and trends of electronic clinical outcome assessment solutions industry provide a holistic approach to this study.

Market Segmentation:

This section of the electronic clinical outcome assessment solutions market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Delivery Mode

  • On-Premise
  • Web & Cloud-Based

By End-User

  • Hospitals/Healthcare Providers
  • CROs
  • Pharmaceutical & Biotechnology Firms
  • Medical Device Companies
  • Others

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Electronic Clinical Outcome Assessment Solutions market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the electronic clinical outcome assessment solutions market include IBM, IQVIA Inc., Medidata Solutions Inc., Clario, ArisGlobal, Signant Health, TransPerfect, Cloudbyz, Clime do Health GmbH, ClinCapture. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Delivery Mode
    • 3.7.2 Market Attractiveness Analysis By End-user
    • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET ANALYSIS BY DELIVERY MODE

  • 6.1 Overview by Delivery Mode
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Delivery Mode
  • 6.4 On-premise Historic and Forecast Sales by Regions
  • 6.5 Web & Cloud-based Historic and Forecast Sales by Regions

7 . GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET ANALYSIS BY END-USER

  • 7.1 Overview by End-user
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-user
  • 7.4 Hospitals/Healthcare Providers Historic and Forecast Sales by Regions
  • 7.5 CROs Historic and Forecast Sales by Regions
  • 7.6 Pharmaceutical & Biotechnology Firms Historic and Forecast Sales by Regions
  • 7.7 Medical Device Companies Historic and Forecast Sales by Regions
  • 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS COMPANIES

  • 9.1. Electronic Clinical Outcome Assessment Solutions Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT SOLUTIONS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. IBM
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. IQVIA Inc.
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Medidata Solutions Inc.
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Clario
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. ArisGlobal
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Signant Health
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. TransPerfect
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Cloudbyz
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. Clime do Health GmbH
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. ClinCapture
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦